Format

Send to

Choose Destination
Eur J Surg Oncol. 2018 Nov;44(11):1773-1778. doi: 10.1016/j.ejso.2018.06.020. Epub 2018 Jul 3.

Quality assurance in melanoma care: The EU-MELACARE study.

Author information

1
Veneto Institute of Oncology IOVIRCCS, Padua, Italy. Electronic address: antonio.sommariva@iov.veneto.it.
2
Carol Davila University of Medicine and Pharmacy, Bucharest, Elias University Hospital, Bucharest, Romania.
3
Malta National Cancer Registry, Malta.
4
Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.
5
Department of Surgery Leiden University Medical Center, Leiden, The Netherlands.
6
Department of Plastic and Reconstructive Surgery, Tuscan Cancer Institute, Italy.
7
Cyprus Cancer Registry, Nicosia, Cyprus.
8
University Hospital Tuebingen, Tuebingen, Germany.
9
Cancer Registry Republic of Srpska, Banja Luka, Republika Srpska, Bosnia and Herzegovina.
10
Institute of Oncology, Ljubljana, Slovenia.
11
Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia.
12
The Cancer Registry of Norway, Institute of Population-based Cancer Research, Oslo, Norway.
13
Netherlands Comprehensive Cancer Organisation, The Netherlands.
14
Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland.
15
Netherlands Cancer Institute, Amsterdam, The Netherlands.
16
Registro Tumori del Veneto, Padua, Italy.
17
Veneto Institute of Oncology IOVIRCCS, Padua, Italy.

Abstract

BACKGROUND:

A significant disparity regarding survival outcome for melanoma among European regions is well recognized and access to high quality care for European melanoma patients needs to be improved. There is an unmet need for the implementation of minimal standard of care within defined clinical pathways and Quality Assurance (QA) indicators.

OBJECTIVE:

The EU-MELACARE study aims to identify shared variables for cutaneous melanoma cases recorded in melanoma registries across Europe.

MATERIAL AND METHODS:

Opinion leaders involved in melanoma data registration and care quality analysis in 34 European countries were invited to respond to an expert survey covering questions regarding the melanoma registration practice in their countries and the characteristics, coverage and variables collected by the relevant melanoma registries.

RESULTS:

Data regarding 13 melanoma registries from 11 European countries contributed to the study. The majority (61,5%) were population based registries and more than half (62%) had national coverage. The included registries collected a median of 38 variables (Interquartile Range, IRQ 21-76). We identified 24 shared variables available in >70% of registries.

CONCLUSIONS:

This study provides valuable specific information on information recorded for melanoma cases are registered within Europe. A core of shared variables has been identified, which will constitute the basis for a standardized set of QA indicators for assessing and monitoring melanoma care across European countries.

KEYWORDS:

Audit; Data registration; Melanoma; Quality assurance

PMID:
30001892
DOI:
10.1016/j.ejso.2018.06.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center